Disrupted Tryptophan Metabolism Induced Cognitive Impairment in a Mouse Model of Sepsis-associated Encephalopathy

Inflammation

Volumn 39, Issue 2, 2016, Pages 550-560

  Gao, Rong ^a   Kan, Ming qiang ^a   Wang, Shi gang ^a   Yang, Run hua ^a   Zhang, Shao gang ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

cognitive impairment; indoleamine 2, 3 dioxygenase; kynurenine; sepsis

Indexed keywords

CYTOKINE; INDOLEAMINE 2,3 DIOXYGENASE; INDOXIMOD; KYNURENINE; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIORAL SCIENCE; CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME ACTIVATION; FEAR CONDITIONING TEST; HIPPOCAMPUS; MALE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; OPEN FIELD TEST; PATHOPHYSIOLOGY; SEPSIS ASSOCIATED ENCEPHALOPATHY; SURVIVAL RATE; TRYPTOPHAN METABOLISM; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CECUM; DISEASE MODEL; METABOLISM; PATHOLOGY; SEPSIS; SURGERY;

ANIMALS; CECUM; COGNITIVE DYSFUNCTION; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MALE; MICE; MICE, INBRED C57BL; SEPSIS; SEPSIS-ASSOCIATED ENCEPHALOPATHY; TRYPTOPHAN;

EID: 84945256502     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-015-0279-x     Document Type: Article

References (29)

1. Iwashyna, T.J., E.W. Ely, D.M. Smith, and K.M. Langa. 2010. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 304(16): 1787–94. doi:10.1001/jama.2010.1553.
2. Girard, T.D., J.C. Jackson, P.P. Pandharipande, B.T. Pun, J.L. Thompson, A.K. Shintani, S.M. Gordon, A.E. Canonico, R.S. Dittus, G.R. Bernard, and E.W. Ely. 2010. Delirium as a predictor of long-term cognitive impairment in survivors of critical illness. Critical Care Medicine 38(7): 1513–20. doi:10.1097/CCM.0b013e3181e47be1.
3. Iwashyna, T.J., C.R. Cooke, H. Wunsch, and J.M. Kahn. 2012. Population burden of long-term survivorship after severe sepsis in older Americans. Journal of American Geriatrics Society 60(6): 1070–7. doi:10.1111/j.1532-5415.2012.03989.x.
4. Gofton, T.E., and G.B. Young. 2012. Sepsis-associated encephalopathy. Nature Reviews Neurology 8(10): 557–66. doi:10.1038/nrneurol.2012.183.
5. Stone, T.W., and L.G. Darlington. 2013. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. British Journal of Pharmacology 169(6): 1211–27. doi:10.1111/bph.12230.
6. Zwilling, D., S.Y. Huang, K.V. Sathyasaikumar, F.M. Notarangelo, P. Guidetti, H.Q. Wu, J. Lee, J. Truong, Y. Andrews-Zwilling, E.W. Hsieh, J.Y. Louie, T. Wu, K. Scearce-Levie, C. Patrick, A. Adame, F. Giorgini, S. Moussaoui, G. Laue, A. Rassoulpour, G. Flik, Y. Huang, J.M. Muchowski, E. Masliah, R. Schwarcz, and P.J. Muchowski. 2011. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145(6): 863–74. doi:10.1016/j.cell.2011.05.020.
7. Wu, W., J.A. Nicolazzo, L. Wen, R. Chung, R. Stankovic, S.S. Bao, C.K. Lim, B.J. Brew, K.M. Cullen, and G.J. Guillemin. 2013. Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer’s disease brain. PloS One 8(4): e59749. doi:10.1371/journal.pone.0059749. Print 2013.
8. Duleu S, Mangas A, Sevin F, Veyret B, Bessede A, and Geffard M. 2010. Circulating antibodies to IDO/THO pathway metabolites in Alzheimer’s disease. Int J Alzheimers Dis 2010. pii: 501541. doi: 10.4061/2010/501541.
9. Savitz, J., R. Dantzer, T.B. Meier, B.E. Wurfel, T.A. Victor, S.A. McIntosh, B.N. Ford, H.M. Morris, J. Bodurka, T.K. Teague, and W.C. Drevets. 2015. Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder. Psychoneuroendocrinology 62: 54–58. doi:10.1016/j.psyneuen.2015.07.609.
10. Savitz, J., W.C. Drevets, C.M. Smith, T.A. Victor, B.E. Wurfel, P.S. Bellgowan, J. Bodurka, T.K. Teague, and R. Dantzer. 2015. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology 40(2): 463–71. doi:10.1038/npp.2014.194.
11. Kegel, M.E., M. Bhat, E. Skogh, M. Samuelsson, K. Lundberg, M.L. Dahl, C. Sellgren, L. Schwieler, G. Engberg, I. Schuppe-Koistinen, and S. Erhardt. 2014. 2014. Imbalanced kynurenine pathway in schizophrenia. International Journal Tryptophan Research 7: 15–22. doi:10.4137/IJTR.S16800.
12. Heisler JM and O’Connor JC. 2015. Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism mediates inflammation-induced deficit in recognition memory. Brain Behav Immun Jun 27. pii: S0889-1591(15)00231-7. doi: 10.1016/j.bbi.2015.06.022.
13. Wu, J., L. Dong, M. Zhang, M. Jia, G. Zhang, L. Qiu, M. Ji, and J. Yang. 2013. Class I histone deacetylase inhibitor valproic acid reverses cognitive deficits in a mouse model of septic encephalopathy. Neurochemical Research 38(11): 2440–9. doi:10.1007/s11064-013-1159-0.
14. Dal-Pizzol, F., H.A. Rojas, E.M. dos Santos, F. Vuolo, L. Constantino, G. Feier, M. Pasquali, C.M. Comim, F. Petronilho, D.P. Gelain, J. Quevedo, J.C. Moreira, and C. Ritter. 2013. Matrix metalloproteinase-2 and metalloproteinase-9 activities are associated with blood–brain barrier dysfunction in an animal model of severe sepsis. Molecular Neurobiology 48(1): 62–70. doi:10.1007/s12035-013-8433-7.
15. Gao, R., Y.H. Tang, J.H. Tong, J.J. Yang, M.H. Ji, and S.H. Zhu. 2015. Systemic lipopolysaccharide administration-induced cognitive impairments are reversed by erythropoietin treatment in mice. Inflammation 38(5): 1949–58. doi:10.1007/s10753-015-0175-4.
16. Xie, W., L. Cai, Y. Yu, L. Gao, L. Xiao, Q. He, Z. Ren, and Y. Liu. 2014. Activation of brain indoleamine 2,3-dioxygenase contributes to epilepsy-associated depressive-like behavior in rats with chronic temporal lobe epilepsy. Journal of Neuroinflammation 11: 41. doi:10.1186/1742-2094-11-41.
17. Anderson, S.T., S. Commins, P.N. Moynagh, and A.N. Coogan. 2015. Lipopolysaccharide-induced sepsis induces long-lasting affective changes in the mouse. Brain, Behavior, and Immunity 43: 98–109. doi:10.1016/j.bbi.2014.07.007.
18. Clark, I.A., and B. Vissel. 2014. Inflammation-sleep interface in brain disease: TNF, insulin, orexin. Journal of Neuroinflammation 11: 51. doi:10.1186/1742-2094-11-51.
19. Hernandes, M.S., J.C. D’Avila, S.C. Trevelin, P.A. Reis, E.R. Kinjo, L.R. Lopes, H.C. Castro-Faria-Neto, F.Q. Cunha, L.R. Britto, and F.A. Bozza. 2014. The role of Nox2-derived ROS in the development of cognitive impairment after sepsis. Journal of Neuroinflammation 11: 36. doi:10.1186/1742-2094-11-36.
20. Wang, J., A.J. Dunn, A.J. Roberts, and H. Zhang. 2009. Decreased immobility in swimming test by homologous interferon-alpha in mice accompanied with increased cerebral tryptophan level and serotonin turnover. Neuroscience Letters 452(2): 96–100. doi:10.1016/j.neulet.2009.01.050.
21. Maes, M., B.E. Leonard, A.M. Myint, M. Kubera, and R. Verkerk. 2011. The new ′5-HT′ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Progress in Neuropsychopharmacology and Biological Psychiatry 35(3): 702–21. doi:10.1016/j.pnpbp.2010.12.017.
22. Lawson, M.A., J.M. Parrott, R.H. McCusker, R. Dantzer, K.W. Kelley, and J.C. O’Connor. 2013. Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors. Journal of Neuroinflammation 10: 87. doi:10.1186/1742-2094-10-87.
23. Dobos, N., E.F. de Vries, I.P. Kema, K. Patas, M. Prins, I.M. Nijholt, R.A. Dierckx, J. Korf, J.A. den Boer, P.G. Luiten, and U.L. Eisel. 2012. The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. Journal of Alzheimer’s Disease 28(4): 905–15. doi:10.3233/JAD-2011-111097.
24. Corona, A.W., D.M. Norden, J.P. Skendelas, Y. Huang, J.C. O’Connor, M. Lawson, R. Dantzer, K.W. Kelley, and J.P. Godbout. 2013. Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice. Brain, Behavior, and Immunity 31: 134–42. doi:10.1016/j.bbi.2012.08.008.
25. Tuon, L., C.M. Comim, F. Petronilho, T. Barichello, I. Izquierdo, J. Quevedo, and F. Dal-Pizzol. 2008. Time-dependent behavioral recovery after sepsis in rats. Intensive Care Medicine 34(9): 1724–31. doi:10.1007/s00134-008-1129-1.
26. Eyre, H., and B.T. Baune. 2012. Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology 37(9): 1397–416. doi:10.1016/j.psyneuen.2012.03.019.
27. Mina, F., C.M. Comim, D. Dominguini, O.J. Cassol-Jr, D.M. Dall Igna, G.K. Ferreira, M.C. Silva, L.S. Galant, E.L. Streck, J. Quevedo, and F. Dal-Pizzol. 2014. l1-β involvement in cognitive impairment after sepsis. Molecular Neurobiology 49(2): 1069–76. doi:10.1007/s12035-013-8581-9.
28. Zhang, C., Y. Cheng, H. Wang, C. Wang, S.P. Wilson, J. Xu, and H.T. Zhang. 2014. RNA interference-mediated knockdown of long-form phosphodiesterase-4D (PDE4D) enzyme reverses amyloid-β42-induced memory deficits in mice. Journal of Alzheimer’s Disease 38(2): 269–80. doi:10.3233/JAD-122236.
29. Waterhouse, E.G., and B. Xu. 2009. New insights into the role of brain-derived neurotrophic factor in synaptic plasticity. Molecular and Cellular Neuroscience 42(2): 81–9. doi:10.1016/j.mcn.2009.06.009.